Benitec Biopharma price target raised to $10 from $8 at JMP Securities

JMP Securities raised the firm’s price target on Benitec Biopharma to $10 from $8 and keeps an Outperform rating on the shares after the company issued a quarterly update, reporting progress with the first-in-human trial, the Data and Safety Monitoring Board has cleared the path for dosing a second patient in February, and FiH data are expected in mid-2024. FiH BB-301 data could validate Benitec’s unique silence and replace strategy, and generate significant upside in 2024, the analyst tells investors in a research note.